LNTH · Lantheus Holdings, Inc. · Executive Compensation
$100.61
-1.39 (-1.36%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Market Cap
$6.67B
Shares
65.40M
Volume · Nov 18
946.87K
Avg daily vol (3M)
1.04M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Ludger Dinkelborg | Head of Research and Development | $15,259,597 |
| Brian Markison | Former Chief Executive Officer | $13,919,738 |
| Paul Blanchfield | Former President | $5,435,275 |
| Robert Marshall | Chief Financial Officer and Treasurer | $5,194,964 |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary | $4,966,384 |
| Amanda Morgan | Chief Commercial Officer | $3,304,547 |
| Mary Anne Heino | Executive Chairperson and Chief Executive Officer | $2,173,930 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brian Markison | Chief Executive Officer | $13,400,697 |
| Robert Marshall | Chief Financial Officer and Treasurer | $5,434,796 |
| Paul Blanchfield | President | $5,307,884 |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary | $4,352,332 |
| Etienne Montagut | Former Chief Business Officer | $3,822,319 |
| Jean-Claude Provost | Chief Science Officer | $3,485,343 |
| Amanda Morgan | Chief Commercial Officer | $2,808,706 |
| Mary Anne Heino | Former Chief Executive Officer | $787,596 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | Former Chief Executive Officer | $12,578,845 |
| Paul Blanchfield | President | $5,305,240 |
| Robert Marshall | Chief Financial Officer and Treasurer | $4,326,011 |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary | $3,115,728 |
| Jean-Claude Provost | Chief Science Officer | $3,079,307 |
| Etienne Montagut | Former Chief Business Officer | $2,886,791 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | Former Chief Executive Officer | $9,479,445 |
| Robert Marshall | Chief Financial Officer and Treasurer | $3,559,619 |
| Paul Blanchfield | President | $3,408,763 |
| Etienne Montagut | Former Chief Business Officer | $2,510,736 |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary | $2,393,512 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | Chief Executive Officer | $6,185,143 |
| Robert Marshall | Chief Financial Officer and Treasurer | $2,385,984 |
| Etienne Montagut | Chief Business Officer | $1,684,393 |
| Paul Blanchfield | President | $1,575,480 |
| John Bolla | Former Chief Operations Officer | $1,438,028 |
| Dr. Istvan Molnar | Former Chief Medical Officer | $1,204,151 |
| Daniel M. Niedzwiecki | Senior Vice President, General Counsel and Corporate Secretary | $1,139,696 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | President and Chief Executive Officer | $4,326,357 |
| Robert Marshall | Chief Financial Officer and Treasurer | $1,324,590 |
| Michael P. Duffy | Senior Vice President, Law and Public Policy and General Counsel | $1,097,830 |
| John Bolla | Former Chief Operations Officer | $1,054,508 |
| Dr. Istvan Molnar | Former Chief Medical Officer | $980,068 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | President & Chief Executive Officer | $4,320,908 |
| Robert Marshall | Chief Financial Officer and Treasurer | $1,435,394 |
| Michael P. Duffy | Senior Vice President, Law and Public Policy and General Counsel | $1,296,700 |
| Cesare Orlandi M.D | Former Chief Medical Officer | $1,064,571 |
| John Bolla | Former Chief Operations Officer | $1,044,888 |
| Simon Robinson Ph.D | Senior Vice President, Research and Pharma Development | $1,010,221 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | President and Chief Executive Officer | $3,913,933 |
| Michael P. Duffy | Senior Vice President, Law and Public Policy and General Counsel | $1,198,257 |
| Cesare Orlandi M.D | Former Chief Medical Officer | $1,133,583 |
| Robert Marshall | Chief Financial Officer | $974,734 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Mary Anne Heino | President and Chief Executive Officer | $3,706,014 |
| Michael P. Duffy | Senior Vice President, Law and Public Policy and General Counsel | $1,209,546 |
| Cesare Orlandi M.D | Former Chief Medical Officer | $1,052,625 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Phuong Khanh (P.K.) Morrow | Class II director | Appointed | 2026-05-01 |
| Julie McHugh | Class II director |
Already on the board
Since at least 2017: re-election or new board role
|
2026-05-01 |
| Heinz Mäusli | Class II director | Appointed | 2026-05-01 |
| Minnie Baylor-Henry | Class II director |
Already on the board
Since at least 2022: re-election or new board role
|
2026-05-01 |
| Brian Markison | Chief Executive Officer | Retired | 2025-11-12 |
| Mary Anne Heino | Interim Chief Executive Officer | Appointed | 2025-11-06 |
| Paul Blanchfield | President | Resigned | 2025-11-06 |
| Mary Anne Heino | Executive Chair | Appointed | 2025-11-06 |
|
Brian Markison
“Mr. Markison's decision to retire from all positions held at the Company is not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.”
|
member of the Company's board of directors | Resigned | 2025-11-06 |
|
Brian Markison
“Mr. Markison's decision to retire from all positions held at the Company is not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.”
|
Chief Executive Officer | Retired | 2025-11-06 |
| Phuong Khanh (P.K.) Morrow, M.D. | Class II Director | Appointed | 2025-01-30 |
| Julie Eastland | Class I Director | Appointed | 2024-09-05 |
| Kimberly Brown | principal accounting officer | Appointed | 2024-06-24 |
| Kimberly Brown | Chief Accounting Officer | Appointed | 2024-06-24 |
| Jeffrey S. Humphrey MD | Chief Medical Officer | Appointed | 2024-05-15 |
| Dr. James H. Thrall | Class III director |
Already on the board
Since at least 2018: re-election or new board role
|
2024-04-29 |
| Gary Pruden | Class III director | Appointed | 2024-04-29 |
| Brian Markison | Class III director | Appointed | 2024-04-29 |
| Julie McHugh | Lead Independent Director | Appointed | 2024-01-23 |
| Brian Markison | Chief Executive Officer | Appointed | 2024-01-23 |
| Brian Markison | Executive Chairman | Appointed | 2024-01-23 |
| Mary Anne Heino | Chair of the Board | Appointed | 2024-01-23 |
| Mary Anne Heino | Chief Executive Officer | Retired | 2024-01-23 |
| Julie McHugh | Class II director |
Already on the board
Since at least 2017: re-election or new board role
|
2023-05-01 |
| Heinz Mäusli | Class II director | Appointed | 2023-05-01 |
Leadership
- Brian Markison CEO, Chairman, Board Member
- Mary Anne Heino CEO, Chairman, Board Member
- Robert Marshall CFO
- Paul Blanchfield COO
- Daniel M. Niedzwiecki General Counsel
- Andrea Sabens Chief Accounting Officer
- Kimberly Brown Chief Accounting Officer
- Dr. Gérard Ber Board Member
- Dr. James H. Thrall Board Member
- Dr. Phuong Khanh (P.K.) Morrow Board Member
- Gary J. Pruden Board Member
- Gary Pruden Board Member
- Heinz Mäusli Board Member
- Julie Eastland Board Member
- Julie McHugh Board Member
- Minnie Baylor-Henry Board Member
- Phuong Khanh (P.K.) Morrow, M.D. Board Member
- Samuel Leno Board Member
Key facts
CIK
1521036
CUSIP
516544103
13F (30d)
450 filings
402 filers
Visit website
Investor relations